Development of the method for assessment and control of the data management system in clinical trials based on key risk indicators
DOI:
https://doi.org/10.24959/cphj.15.1336Keywords:
clinical trial, risk management, key risk indicator, data quality, trial siteAbstract
Qualitative data are one of the essential elements of the clinical trial quality; they contribute to the evidence-based substantiation of efficacy and safety of a drug making a great impact on success of its approval by regulatory bodies. The paper outlines the method for assessment and control of the data management system in clinical trials based on key risk indicators (KRI). According to the most important characteristics of the project implementation, the list of KRIs, including such three categories as time, cost/resources and scope/quality, has been proposed. The approaches to KRIs interpretation have been also identified; they involve the use of specific intervals of KRIs values (target, threatening, critical). The algorithm of KRIs application and interpretation has been developed. Based on the method suggested we have evaluated the process of case report form completion in Clinical-diagnostic Centre of the National University of Pharmacy as a one of the most important process of the data management system in clinical trial related to numerous data quality loss risks.References
Доброва В.Є., Зупанець К.О., Ратушна К.Л. та ін. // Управління, економіка та забезпечення якості в фармації. – 2013. – №5 (31). – С. 16-23.
Доброва В.Є., Зупанець К.О., Ратушна К.Л. // Клінічна фармація. – 2014. – №1 (18). – С. 4-10.
Захожай В.Б., Чорний А.Ю. Статистичне забезпечення управління якістю: Навч. посіб. – К.: Центр навчальної літератури, 2005. – 340 с.
Зупанець К.О., Ратушна К.Л., Доброва В.Є., Андрєєва О.О. // Клінічна фармація. – 2014. – №4 (18). – С. 23-31.
Клинические испытания лекарств / Под ред. В.И.Мальцева, Т.И.Ефимцевой, Ю.Б.Белоусова и др. – 2-е изд., перераб. и доп. – К.: МОРИОН, 2006. – 456 с.
Наказ МОЗ України №690 від 23.09.2009 «Порядок проведення клінічних випробувань лікарських засобів та експертизи матеріалів клінічних випробувань. – Режим доступа: http://zakon.rada.gov.ua/cgi-bin/laws/main.cgi?nreg=z1010-09.
Мазур И.И., Шапиро В.Д., Ольдерогге Н.Г. Управление проектами: Учеб. пособ. / Под общ. ред. И.И.Мазура. – 2-е изд. – М.: Омега-Л, 2004. – 664 c.
Настанова СТ-Н МОЗУ 42-7.0:2008 Лікарські засоби. Належна клінічна практика. – К., 2009. – 67 с.
Настанова СТ-Н МОЗУ 42-4.2:2011 Лікарські засоби. Управління ризиками для якості. – К., 2011. – 26 с.
Сагайдак-Нікітюк Р.В. Посилкіна О.В. // Укр. журн. клін. та лабораторної медицини. – 2010. – №1. – С. 8-12.
Alemayehu D., Alvir J., Chappell P.B. et al. // Applied Clin. Trials. – 2012. – Vol. 5. – P. 15-16.
Brosteanu O., Houben P., Ihrig K. et al. // Clin. Trials. – 2009. – Vol. 6. – P. 585-596.
Djali S., Janssens S., Yper S. // Drug Information J. – 2010. – Vol. 44. – P. 359-373.
European Medicine Agency. Reflection paper on risk based management in clinical trials. – Режим доступа: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110059.pdf
Gregg H. Claycamp // Drug Information J. – 2007. – Vol. 41. – P. 353-367.
Immaneni A., Mastro Ch., Haubenstock M. // Operational Risk: A Special Edition of The RMA Journal. – 2004. – P. 42-47.
MRC/DH/MHRA joint project; Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Режим доступа: http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clinicaltrials/index.html
Robinson M., Cook S. Clinical Trial Risk Management. – Boca Raton: Francis and Taylor, 2006. – 211 p.
Rosenberg M.J. // Therapeutic Innovation and Regulatory Sci. – №48 (4). – P. 428-435.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
